Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma

DOI: 10.1111/liv.13639
Liver International, 2018, 38, 1074-1083.

#	Paper	IF	Citations
63	FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. *Cancer Medicine*, **2018**, 7, 2629-2640	4.8	33
62	Alpha-syntrophin deficient mice are protected from adipocyte hypertrophy and ectopic triglyceride deposition in obesity. *Experimental and Molecular Pathology*, **2018**, 104, 212-221	4.4	4
61	High expression of FABP4 and FABP6 in patients with colorectal cancer. *World Journal of Surgical Oncology*, **2019**, 17, 171	3.4	17
60	Molecular cloning, characterisation, and expression analysis of adipocyte fatty acid binding protein gene in Xupu goose (). *British Poultry Science*, **2019**, 60, 659-665	1.9	3
59	Role of fatty acid binding proteins (FABPs) in cancer development and progression. *Cellular Signalling*, **2019**, 62, 109336	4.9	30
58	Associations between Fatty Acid-Binding Protein 4?A Proinflammatory Adipokine and Insulin Resistance, Gestational and Type 2 Diabetes Mellitus. *Cells*, **2019**, 8,	7.9	26
57	Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases. *Journal of Atherosclerosis and Thrombosis*, **2019**, 26, 216-232	4	77
56	microRNA-211 promotes invasion and migration of colorectal cancer cells by targeting FABP4 via PPAR*Journal of Cellular Physiology*, **2019**, 234, 15429	7	12
55	Fatty acid-binding proteins: functional understanding and diagnostic implications. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2019**, 22, 407-412	3.8	13
54	Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome. *Oncogene*, **2019**, 38, 3033-3046	9.2	24
53	Non-Coding and Regulatory RNAs as Epigenetic Remodelers of Fatty Acid Homeostasis in Cancer. *Cancers*, **2020**, 12,	6.6	2
52	Transcriptomic Data Analyses Reveal a Reprogramed Lipid Metabolism in HCV-Derived Hepatocellular Cancer. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 581863	5.7	2
51	Proteomic analysis revealed common, unique and systemic signatures in gender-dependent hepatocarcinogenesis. *Biology of Sex Differences*, **2020**, 11, 46	9.3	4
50	Computational Drug Repurposing Approach to Identify Potential Fatty Acid-Binding Protein-4 Inhibitors to Develop Novel Antiobesity Therapy. *Assay and Drug Development Technologies*, **2020**, 18, 318-327	2.1	9
49	The Effect of Silibinin on Protein Expression Profile in White Adipose Tissue of Obese Mice. *Frontiers in Pharmacology*, **2020**, 11, 55	5.6	5
48	The expression signatures in liver and adipose tissue from obese G□ttingen Minipigs reveal a predisposition for healthy fat accumulation. *Nutrition and Diabetes*, **2020**, 10, 9	4.7	5
47	Huang-Qi San improves glucose and lipid metabolism and exerts protective effects against hepatic steatosis in high fat diet-fed rats. *Biomedicine and Pharmacotherapy*, **2020**, 126, 109734	7.5	12

46	Berberine Suppressed Tumor Growth through Regulating Fatty Acid Metabolism and Triggering Cell Apoptosis via Targeting FABPs. *Evidence-based Complementary and Alternative Medicine*, **2020**, 2020, 6195050	2.3	5
45	Expression of Protein Markers of Adipogenesis in Endometriotic Lesions. *Cell and Tissue Biology*, **2020**, 14, 129-138	0.4	1
44	Fatty acid binding protein-4 promotes alcohol-dependent hepatosteatosis and hepatocellular carcinoma progression. *Translational Oncology*, **2021**, 14, 100975	4.9	3
43	FABP4 and omentin-1 gene expression in epicardial adipose tissue from coronary artery disease patients. *Genetics and Molecular Biology*, **2021**, 44, e20200441	2	0
42	Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes. *Journal of Hepatocellular Carcinoma*, **2021**, 8, 45-55	5.3	6
41	Decellularized biologic muscle-fascia abdominal wall scaffold graft. *Surgery*, **2021**, 169, 595-602	3.6	
40	Serum fatty acid-binding protein 5 is a significant factor in hepatocellular carcinoma progression independent of tissue expression level. *Carcinogenesis*, **2021**, 42, 794-803	4.6	0
39	Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. *British Journal of Pharmacology*, **2021**, 178, 2412-2423	8.6	12
38	Lampaya Medicinalis Phil. decreases lipid-induced triglyceride accumulation and proinflammatory markers in human hepatocytes and fat body of Drosophila melanogaster. *International Journal of Obesity*, **2021**, 45, 1464-1475	5.5	1
37	FABP4 deactivates NF-κB-IL1β pathway by ubiquitinating ATPB in tumor-associated macrophages and promotes neuroblastoma progression. *Clinical and Translational Medicine*, **2021**, 11, e395	5.7	4
36	Tandem mass tag-based proteomics for studying the effects of a biotechnologically produced oyster mushroom against hepatic steatosis in obese Zucker rats. *Journal of Proteomics*, **2021**, 242, 104255	3.9	0
35	Effect of Compounds from Moringa oleifera Lam. on in Vitro Non-Alcoholic Fatty Liver Disease (NAFLD) Model System. *Chemistry and Biodiversity*, **2021**, 18, e2100243	2.5	
34	Combined treatment with FABP4 inhibitor ameliorates rosiglitazone-induced liver steatosis in obese diabetic db/db mice. *Basic and Clinical Pharmacology and Toxicology*, **2021**, 129, 173-182	3.1	1
33	Transcriptome profiling of hepatic and renal mRNAs and lncRNAs under a nutritional restriction during pregnancy in a sheep model. *Genomics*, **2021**, 113, 2769-2779	4.3	
32	PXR-mediated expression of FABP4 promotes valproate-induced lipid accumulation in HepG2 cells. *Toxicology Letters*, **2021**, 346, 47-56	4.4	1
31	Proteomic Analysis of Niemann-Pick Type C Hepatocytes Reveals Potential Therapeutic Targets for Liver Damage. *Cells*, **2021**, 10,	7.9	2
30	A Multi-Omics Human Liver Organoid Screening Platform for DILI Risk Prediction.		0
29	A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	0

28	HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway. *Aging*, **2019**, 11, 10839-10860	5.6	27
27	Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. *International Journal of Biological Sciences*, **2021**, 17, 4207-4222	11.2	7
26	Identification of hub genes and key pathways of dietary advanced glycation end products-induced non-alcoholic fatty liver disease by bioinformatics analysis and animal experiments. *Molecular Medicine Reports*, **2020**, 21, 685-694	2.9	5
25	FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE mice atherosclerosis. *Laboratory Investigation*, **2021**,	5.9	2
24	[miR-203 inhibits lung cancer cell metastasis by targeting fatty acid binding protein 4]. *Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University*, **2018**, 38, 578-583	0.5	1
23	25-HC promotes hepatocellular carcinoma metastasis through up-regulation of TLR4 dependent FABP4. *American Journal of Cancer Research*, **2019**, 9, 2140-2155	4.4	3
22	Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease.. *Biomedicines*, **2022**, 10,	4.8	1
21	A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.. *Journal of Oncology*, **2022**, 2022, 3822773	4.5	0
20	Circulating level of FABP4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. *Journal of Diabetes Investigation*, **2021**,	3.9	0
19	Maternal supply of a source of omega-3 fatty acids and methionine during late gestation on the offspring♀ growth, metabolism, carcass characteristic, and liver♀ mRNA expression in sheep.. *Journal of Animal Science*, **2022**,	0.7	
18	Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice.. *Bioengineered*, **2022**, 13, 6750-6766	5.7	0
17	Fatty acid binding protein 4 regulates pancreatic cancer cell proliferation via activation of nuclear factor E2-related factor 2.. *Surgery for Obesity and Related Diseases*, **2021**,	3	2
16	Cytochrome P450 2E1 dependent hepatic ethanol metabolism induces fatty acid binding protein 4 and steatosis.. *Alcoholism: Clinical and Experimental Research*, **2022**,	3.7	0
15	Image_1.PDF. **2020**,		
14	Image_2.JPEG. **2020**,		
13	Table_1.XLSX. **2020**,		
12	Table_2.XLSX. **2020**,		
11	Table_3.XLSX. **2020**,		

10	Cytoplasmic fatty acid-binding proteins in metabolic diseases and cancers. *Advances in Protein Chemistry and Structural Biology*, **2022**,	5.3	
9	Novel Paired Cell Lines for the Study of Lipid Metabolism and Cancer Stemness of Hepatocellular Carcinoma. *Frontiers in Cell and Developmental Biology*, 10,	5.7	1
8	<i>FABP4</i> gene expression in subcutaneous and visceral adipose tissue in patients with obesity and type 2 diabetes mellitus. *Uchenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova*, **2022**, 29, 46-53	0.2	
7	FABP4 in obesity-associated carcinogenesis: Novel insights into mechanisms and therapeutic implications. 9,		0
6	Mechanism of paracrine communications between hepatic progenitor cells and endothelial cells. **2022**, 100, 110458		0
5	Effect of theaflavin-3,3?-digallate on leptin-deficient induced nonalcoholic fatty liver disease might be related to lipid metabolism regulated by the Fads1/PPARγ/Fabp4 axis and gut microbiota. 13,		0
4	Role of AMPK-SREBP Signaling in Regulating Fatty Acid Binding-4 (FABP4) Expression following Ethanol Metabolism. **2022**, 11, 1613		1
3	Millet Bran Protein Hydrolysate Displays the Anti-non-alcoholic Fatty Liver Disease Effect via Activating Peroxisome Proliferator-Activated Receptor α to Restrain Fatty Acid Uptake.		0
2	A human liver organoid screening platform for DILI risk prediction. **2023**, 78, 998-1006		0
1	The therapeutic effects of berberine for gastrointestinal cancers.		0